In Vitro and In Vivo Evaluation of Melanin-Binding Decapeptide 4B4 Radiolabeled with super(177)Lu, super(166)Ho, and super(153)Sm Radiolanthanides for the Purpose of Targeted Radionuclide Therapy of Melanoma
Melanoma is a malignancy with increasing incidence. Although primary tumors that are localized to the skin can be successfully treated by surgical removal, there is no satisfactory treatment for metastatic melanoma, a condition that has currently an estimated 5-year survival of just 6%. During the l...
Saved in:
Published in | Cancer biotherapy & radiopharmaceuticals Vol. 26; no. 5; pp. 547 - 556 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2011
|
Online Access | Get full text |
Cover
Loading…
Abstract | Melanoma is a malignancy with increasing incidence. Although primary tumors that are localized to the skin can be successfully treated by surgical removal, there is no satisfactory treatment for metastatic melanoma, a condition that has currently an estimated 5-year survival of just 6%. During the last decade, beta - or alpha -emitter-radiolabeled peptides that bind to different receptors on a variety of tumors have been investigated as potential therapeutic agents in both the preclinical and clinical settings with encouraging results. A recent study demonstrated that 188-Rhenium ( super(188)Re)-labeled, via HYNIC ligand, fungal melanin-binding decapeptide 4B4 was effective against experimental MNT1 human melanoma and was safe to normal melanized tissues. The availability of radiolanthanides with diverse nuclear emission schemes and half-lives provides an opportunity to expand the repertoire of peptides for radionuclide therapy of melanoma. The melanin-binding decapeptide 4B4 was radiolabeled with super(177)Lu, super(166)Ho, and super(153)Sm via a DO3A chelate. The stability studies of Ln*-DO3A-4B4 in phosphate-buffered saline, serum, and a hydroxyapatite assay demonstrated that super(177)Lu-labeled peptide was more stable than super(166)Ho- and super(153)Sm-labeled peptides, most likely because of the smallest ionic radius of the former allowing for better complexation with DO3A. Binding of Ln*-DO3A-4B4 to the lysed highly melanized MNT1 melanoma cells demonstrated the specificity of peptides binding to melanin. In vivo biodistribution data for super(177)Lu-DO3A-4B4 given by intraperitoneal administration to lightly pigmented human metastatic A2058 melanoma-bearing mice demonstrated very high uptake in the kidneys and low tumor uptake. Intravenous administration did not improve the tumor uptake. The plausible explanation of low tumor uptake of super(177)Lu-DO3A-4B4 could be its decreased ability to bind to melanin during in vitro binding studies in comparison with super(188)Re-HYNIC-4B4, exacerbated by the very fast clearance from the blood and the kidneys "sink" effect. |
---|---|
AbstractList | Melanoma is a malignancy with increasing incidence. Although primary tumors that are localized to the skin can be successfully treated by surgical removal, there is no satisfactory treatment for metastatic melanoma, a condition that has currently an estimated 5-year survival of just 6%. During the last decade, beta - or alpha -emitter-radiolabeled peptides that bind to different receptors on a variety of tumors have been investigated as potential therapeutic agents in both the preclinical and clinical settings with encouraging results. A recent study demonstrated that 188-Rhenium ( super(188)Re)-labeled, via HYNIC ligand, fungal melanin-binding decapeptide 4B4 was effective against experimental MNT1 human melanoma and was safe to normal melanized tissues. The availability of radiolanthanides with diverse nuclear emission schemes and half-lives provides an opportunity to expand the repertoire of peptides for radionuclide therapy of melanoma. The melanin-binding decapeptide 4B4 was radiolabeled with super(177)Lu, super(166)Ho, and super(153)Sm via a DO3A chelate. The stability studies of Ln*-DO3A-4B4 in phosphate-buffered saline, serum, and a hydroxyapatite assay demonstrated that super(177)Lu-labeled peptide was more stable than super(166)Ho- and super(153)Sm-labeled peptides, most likely because of the smallest ionic radius of the former allowing for better complexation with DO3A. Binding of Ln*-DO3A-4B4 to the lysed highly melanized MNT1 melanoma cells demonstrated the specificity of peptides binding to melanin. In vivo biodistribution data for super(177)Lu-DO3A-4B4 given by intraperitoneal administration to lightly pigmented human metastatic A2058 melanoma-bearing mice demonstrated very high uptake in the kidneys and low tumor uptake. Intravenous administration did not improve the tumor uptake. The plausible explanation of low tumor uptake of super(177)Lu-DO3A-4B4 could be its decreased ability to bind to melanin during in vitro binding studies in comparison with super(188)Re-HYNIC-4B4, exacerbated by the very fast clearance from the blood and the kidneys "sink" effect. |
Author | Revskaya, E Dadachova, E Jiang, Z Francesconi, L C Ballard, B Soil, CE Cutler, C S |
Author_xml | – sequence: 1 givenname: B surname: Ballard fullname: Ballard, B – sequence: 2 givenname: Z surname: Jiang fullname: Jiang, Z – sequence: 3 givenname: CE surname: Soil fullname: Soil, CE – sequence: 4 givenname: E surname: Revskaya fullname: Revskaya, E – sequence: 5 givenname: C surname: Cutler middlename: S fullname: Cutler, C S – sequence: 6 givenname: E surname: Dadachova fullname: Dadachova, E – sequence: 7 givenname: L surname: Francesconi middlename: C fullname: Francesconi, L C |
BookMark | eNqNjjtPw0AQhK8IEglQ0m8HlmJzfsdtIChIICGwaKOLvY4Pne_MPRLxK_lLOFFCTbWa0Tc7MyEjqSQSch3SIKSz4q5a6yCiYRjQIk1GZDyYiV_ks_ScTIz5pJRmNMvH5OdJwge3WgGTNRzEVsFiy4RjlisJqoEXFExy6c-5rLncwANWrMfe8hohmSfwxmquBFujwBp23LZgXI_6Nsxz79lNTyrLvKWaHnqOThp7790pLm07tNRooFEabIvw6nSvDO4nlExv0A7vD7B0ldiXly1q1n__bVQduyRnDRMGr473gtw8Lsr7pd9r9eXQ2FXHTYVioFE5sypoHhZxFGXx_8lfGUlzmw |
ContentType | Journal Article |
DBID | 7QO 8FD FR3 P64 |
DOI | 10.1089/cbr.2011.0954 |
DatabaseName | Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Biotechnology Research Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EndPage | 556 |
GroupedDBID | --- 0R~ 29B 3V. 4.4 53G 5GY 5RE 6PF 7QO 7X7 88A 88E 88I 8C1 8FD 8FE 8FH 8FI 8FJ AAWTL ABBKN ABJNI ABUWG ACGFS ACGOD ACPRK ADBBV AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BNQNF BPHCQ BVXVI CAG CCPQU COF CS3 DU5 DWQXO EBS EJD F5P FR3 FYUFA GNUQQ HCIFZ HMCUK IAO IHR IM4 INH INR ITC L7B LK8 M0L M1P M2P M7P O9- P2P P64 PQQKQ PROAC PSQYO RIG RML UE5 UKHRP |
ID | FETCH-proquest_miscellaneous_9071932263 |
ISSN | 1084-9785 |
IngestDate | Sat Aug 17 00:53:53 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_miscellaneous_9071932263 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-1 |
PQID | 907193226 |
PQPubID | 23462 |
ParticipantIDs | proquest_miscellaneous_907193226 |
PublicationCentury | 2000 |
PublicationDate | 20111001 |
PublicationDateYYYYMMDD | 2011-10-01 |
PublicationDate_xml | – month: 10 year: 2011 text: 20111001 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Cancer biotherapy & radiopharmaceuticals |
PublicationYear | 2011 |
SSID | ssj0006067 |
Score | 3.8883932 |
Snippet | Melanoma is a malignancy with increasing incidence. Although primary tumors that are localized to the skin can be successfully treated by surgical removal,... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 547 |
Title | In Vitro and In Vivo Evaluation of Melanin-Binding Decapeptide 4B4 Radiolabeled with super(177)Lu, super(166)Ho, and super(153)Sm Radiolanthanides for the Purpose of Targeted Radionuclide Therapy of Melanoma |
URI | https://search.proquest.com/docview/907193226 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe6TkK8IBggYDDdAxpUbVk_8uVHWjp1U1eqNkN9q5zEE9G2eGqbSuWf5IU_iHPsONmGNODFqq3IdnI_nX13v7sS8h7P2IgybjWtKAjQQLlwmzSwUBnantdmbmixzFA8GzvDc-t0bs8rlV8l1lK6Dj6FP_6YV_I_UsUxlKvMkv0HyZpJcQB_o3yxRQlj-1cyPknq3-L1UmhSL3Y2oj4w9bszegu_YkmcNHuxSl_5wiXjCfVExOtWz6pPWRSjdRvg6RPlfPUbKUYvC7PSUSqFYMYctMHpUOScTzMu_9WCzq7z6RLpkMclVobFOEGBChU38DPyOS6XPZyk4ZXcjK_KG5g9C31gFFUUQr6sB7HOGFNEn6Wc4eZ72S1fuP1liEAR901Y6TTW7nETj5kJ5QTvm4yMKd-sLtmWFWkakfHy5vS6XI-3PKuJBrJdVvQqNV8D2i5pbVsV_dQXAFtVOr93trQ8WZo1DJa68CtV1a9v1_Aef10cn49GC38w93fIbseltl0lu73BeDI1NwQ0Gl2V-KE2qWu_4gJHt6a_dz_ILj3-U_JEWyvwWUHvGanwZI88OtN8jD1yOFHfftsAv0jkWzXgECZFTfTtc_LzJIEMqoCwgayzEVBAFcQF3IEqlKAKCFUoQxUkVCGD30cEam2UNvKe49SGopGto0fsbm12DXehCQhNQDCBhqbcQg5NKENTv9rW7BGh-YJ8OB74_WEz_3IL1JcyCMYSLtLVguKdGm2WjtN9SaqJSPgrAhHjTtQJOhFzueVZodcK2jJ8TCmjYbcbvibw0GxvHn5knzwuoPqWVNfLlL_DG-06OCA77tzF1uu3DzRYfgN-w6w6 |
link.rule.ids | 315,786,790,27955,27956,31753,33300,33778 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vitro+and+In+Vivo+Evaluation+of+Melanin-Binding+Decapeptide+4B4+Radiolabeled+with+super%28177%29Lu%2C+super%28166%29Ho%2C+and+super%28153%29Sm+Radiolanthanides+for+the+Purpose+of+Targeted+Radionuclide+Therapy+of+Melanoma&rft.jtitle=Cancer+biotherapy+%26+radiopharmaceuticals&rft.au=Ballard%2C+B&rft.au=Jiang%2C+Z&rft.au=Soil%2C+CE&rft.au=Revskaya%2C+E&rft.date=2011-10-01&rft.issn=1084-9785&rft.volume=26&rft.issue=5&rft.spage=547&rft.epage=556&rft_id=info:doi/10.1089%2Fcbr.2011.0954&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1084-9785&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1084-9785&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1084-9785&client=summon |